Ruxolitinib

Drug Profile

Ruxolitinib

Alternative Names: INC-424; INCB-018424; INCB-18424; Jakafi; Jakavi

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Lymphoma Academic Research Organisation; Novartis; RWTH Aachen University; Sunnybrook Health Sciences Centre; University Health Network of Toronto; University of Cologne; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Antineoplastics; Antipsoriatics; Antirheumatics; Cyclopentanes; Nitriles; Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Pancreatic cancer; Polycythaemia vera; Essential thrombocythaemia; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelofibrosis; Polycythaemia vera
  • Phase III Essential thrombocythaemia; Graft-versus-host disease
  • Phase II Acute lymphoblastic leukaemia; Alopecia areata; Atopic dermatitis; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Thalassaemia
  • Phase I/II Acute myeloid leukaemia; Chronic myeloid leukaemia
  • No development reported Psoriasis
  • Discontinued Breast cancer; Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 24 Apr 2017 Incyte Corporation plans a phase II trial for Essential thrombocythaemia (Treatment-resistant) (NCT03123588)
  • 06 Apr 2017 Incyte Corporation plans a phase II trial for Vitiligo (In children, In adolescents, In adults) in USA (NCT03099304)
  • 04 Apr 2017 Novartis plans regulatory filings for Graft-versus-host disease in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top